anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Estimate the maximum tolerated dose of continuous infusion interleukin-2 (IL-2) that can be combined with a standard dose of filgrastim (G-CSF) to stimulate peripheral blood stem cells (PBSC) for harvest in patients with advanced breast cancer. II. Assess PBSC engraftment following high dose cyclophosphamide, thiotepa, and carboplatin (the STAMP V regimen) supported by G-CSF or IL-2/G-CSF hematopoietic support in patients who underwent the same pretransplant PBSC stimulation. III. Characterize the toxic effects of combined IL-2 and G-CSF. IV. Compare immune function changes following IL-2/G-CSF and G-CSF alone by assessing expression of CD56/CD56-bright, CD3, and CD25; natural killer cell and lymphokine activated killer cell activity; T-cell responses (TT, HER2/neu); and serum levels of interleukin-6, tumor necrosis factor, and G-CSF. V. Compare the effects on the expression of circulating hematopoietic progenitor cells (CD34+, CFU-GM, and BFU-GM) of a range of IL-2 doses when combined with G-CSF to those achieved with G-CSF alone. VI. Compare the time to neutrophil and platelet recovery, requirements for red blood cell and platelet transfusion, and time to hospital discharge in patients receiving IL-2/G-CSF-primed vs. G-CSF-primed PBSC following STAMP V chemotherapy. VII. Compare the feasibility, toxicity, and hematologic and immunologic effects of post-PBSC infusion of IL-2/G-CSF vs. G-CSF alone. VIII. Assess the response rate, duration of response, and disease free interval of patients with advanced breast cancer treated with STAMP V with PBSC rescue. IX. Assess the presence of cytokeratin as a marker of minimum residual disease when measured in blood and marrow by polymerase chain reaction during and following treatment.

OUTLINE: Patients are assigned to 1 of 4 treatment groups for peripheral blood stem cell stimulation (priming) and for therapy after stem cell transplantation. All patients receive priming therapy with filgrastim (G-CSF) alone or with interleukin-2 (IL-2), then have stem cells harvested. Patients with adequate harvest receive high dose cyclophosphamide, thiotepa, and carboplatin (STAMP V) followed by stem cell rescue with subsequent G-CSF with or without IL-2, as follows: Arm I receives G-CSF alone for priming and following stem cell transplant. Arm II receives G-CSF priming alone and G-CSF/IL-2 following transplant. Arm III receives various doses of G-CSF/IL-2 priming and G-CSF following transplant. Arm IV receives various levels of G-CSF/IL-2 priming and fixed doses of G-CSF/IL-2 following transplant. Cohorts of 3-6 patients each are treated on each treatment arm and at escalating doses of IL-2. The maximum tolerated dose is defined as the dose at which less than 2 of 6 patients experience dose limiting toxicity. Patients are followed for disease progression and survival.

PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study over 18-24 months; a maximum of 12 patients will receive G-CSF priming alone (6 without and 6 with post-PBSC IL-2).
The use of a combination of a first polymer and a second polymer as a taste-masking agent for an active pharmaceutical ingredient (API) and pharmaceutically acceptable salts or esters thereof, wherein the API is selected from expectorants, antitussives, mucolytics, erectile dysfunction medicaments and analgesics other than NSAIDs, wherein the API and the combination of the first and second polymer are in the form of a solidified melt extrudate is provided. A taste-masked composition in the form of a solidified melt extrudate comprising an API selected from analgesics other than NSAIDs, expectorants, antitussives, mucolytics and erectile dysfunction medicaments, and a combination of a first and second polymer as defined therein is provided. The API may be paracetamol (analgesic other than NSAIDs), guaifenesin (expectorant), sildenafil (erectile dysfunction medicament) or dextromethorphan (antitussive). The first polymer may be selected from polymethacrylates such as amino methacrylate copolymer, amino-methyl methacrylate, methacrylic acid, methyl methacrylate, dimethyl aminoethyl methacrylate co-polymer. The second polymer may be selected from polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate co-polymer and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and polyvinyl alcohol. Preferred combinations of polymers are dimethylaminoethyl methacrylate co-polymer (Eudragit® E PO) and polyvinylpyrrolidone-vinyl acetate co-polymer (PVPVA64), and dimethylaminoethyl methacrylate co-polymer (Eudragit® E PO) and polyvinyl alcohol.
A computer system hosts a centralized data repository and a fulfillment platform. The centralized data repository receives clinical data corresponding to patients from multiple remote clinical data sources, aggregates the received clinical data, and normalizes the aggregated clinical data. The received clinical data may be pre-filtered based on patient consent. The fulfillment platform receives requests from requester computing devices, e.g., biological specimen requests or requests for prospective patients for a clinical study. The requests include cohort definitions. The fulfillment platform performs queries on the aggregated clinical data based on the requests, identifies matches in the aggregated clinical data in response to the queries, and transmits notifications to source site computing devices (e.g., dedicated tablet devices) for the identified matches. The notifications may identify, for example, matching biological specimens or prospective patients for clinical trials.
Gestational diabetes is a condition diagnosed during pregnancy that causes blood sugars to rise. Diet and exercise can effectively control blood sugar levels in 70-85% of women diagnosed with gestational diabetes according to the American Diabetes Association. At the investigator's institution, only 50-54% of women with this diagnosis effectively reach the target blood sugar levels with diet and exercise alone. This has become a more commonly seen problem throughout the US. Those that fail to achieve target blood sugar levels require medication and have higher risks of poor maternal and neonatal outcomes. Studies have shown that an increase in education can increase compliance to diet and education. Specifically, media based education that are interactive may more effectively lead to changes in a person's behavior.
This paper presents a novel centrifugal microfluidic approach (so-called lab-on-a-CD) for magnetic circulating tumor cell (CTC) separation from the other healthy cells according to their physical and acquired chemical properties. This study enhances the efficiency of CTC isolation, crucial for cancer diagnosis, prognosis, and therapy. CTCs are cells that break away from primary tumors and travel through the bloodstream; however, isolating CTCs from blood cells is difficult due to their low numbers and diverse characteristics. The proposed microfluidic device consists of two sections: a passive section that uses inertial force and bifurcation law to sort CTCs into different streamlines based on size and shape and an active section that uses magnetic forces along with Dean drag, inertial, and centrifugal forces to capture magnetized CTCs at the downstream of the microchannel. The authors designed, simulated, fabricated, and tested the device with cultured cancer cells and human cells. We also proposed a cost-effective method to mitigate the surface roughness and smooth surfaces created by micromachines and a unique pulsatile technique for flow control to improve separation efficiency. The possibility of a device with fewer layers to improve the leaks and alignment concerns was also demonstrated. The fabricated device could quickly handle a large volume of samples and achieve a high separation efficiency (93%) of CTCs at an optimal angular velocity. The paper shows the feasibility and potential of the proposed centrifugal microfluidic approach to satisfy the pumping, cell sorting, and separating functions for CTC separation.
Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
PURPOSE:The titled stable composition, prepared by adding an ammonium compound and a carboxyvinyl polymer together to an aqueous composition of urea, and adjusting the pH to a specific range, capable of inhibiting the decomposition of urea by the synergistic effect thereof, and useful for a medicinal or cosmetic base. CONSTITUTION:An aqueous jellylike composition prepared by adding 0.5-5wt% ammonium compound, e.g. ammonium chloride or ammonium sulfate, and 0.5- 5wt% carboxyvinyl polymer having preferably within 1,000,000-3,000,000 molecular weight range as an inhibitor for the decomposition of the urea to an aqueous composition containing 1-48wt% urea, and adjusting the pH to 5.5-7.5 with a basic compound, e.g. an alkali metallic hydroxide or alkanolamine, and containing stably incorporated urea. In case the amount of the uea is 1-10wt%, the composition is used as a base for cosmetics having humectant action. If the amount of the urea exceeds 10wt%, the composition is used as a base in medicines having action on the integument utilizing the softening action on keratin.
OBJECTIVE: To evaluate the association of the rs11125908 polymorphism in the COMMD1 gene in the Cuban population with rheumatoid arthritis (RA).
METHODS: In this case-control study, 161 RA patients and 150 control subjects were genotyped for rs11125908 by the allele-specific polymerase chain reaction method. DNA sequencing was used to verify the assignation of the polymorphism. The odds ratios (OR) and their 95% confidence interval were calculated by logistic regression to determine the associations between genotypes and RA using the SNPStats software.
RESULTS: An association of the single nucleotide polymorphism with the disease was found in the overdominant model (p=0.025; OR=1.91) for the AG genotype. Our analyses revealed an association between rs11125908 and the subgroup of patients with swollen joints < median under the codominant model for AG (p=0.034; OR=2.30) and GG genotype (p=0.034; OR=0.82) and with the overdominant model (p=0.01; OR=2.38). The subgroup of patients with an age of onset lower than the mean and AG genotype showed an association in the overdominant model (p=0.027; OR=2.27). Disease activity score 28 with erythrocyte sedimentation rate and disease duration variables were not associated with the rs11125908 polymorphism.
CONCLUSIONS: rs11125908 was associated with RA and with the number of swollen joints and age of onset subgroup analyses. We provide concepts for treatments for RA, based on pharmacological management of COMMD1 expression.
PROBLEM TO BE SOLVED: To provide systems and methods for intra-oral delivery of drugs.SOLUTION: The system enables drugs or therapeutic agents to be delivered through a mouth. The system provides ideal drug delivery for certain diseases relating to periodontics, tooth surface, and endodontics, and diseases associated with cancer and medical conditions. For dental diseases, the system is placed so that release of the therapeutic agent occurs in the immediate vicinity of the disease process. As the volume of distribution is limited to the volume of gum pocket or crevice, relatively high concentrations of therapeutic agent can be delivered by devices with small therapeutic agent reservoir capacities. The small amount of therapeutic agent required under these conditions, typically a few milligrams, greatly reduces the effect of the therapeutic agent at distal sites within the body, thereby greatly decreasing the potential for systemic side effects. Thus, a high degree of effectiveness is achieved using a relatively small amount of drug.
Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
This is an open-label, multicenter, dose-escalation phase I trial that aims to determine the safety and tolerability of TMV-018, an oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase", when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor up to day 72 in patients with colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.

At least 15 patients will be enrolled. Patients will be randomized to different treatment groups: all patients will receive intra-tumoral TMV-018 on four visits and additionally 5-FC and/or anti-PD-1 treatment. All adverse events will be documented and analyzed for the primary safety endpoint. Blood and tumor samples will be collected up to day 72 to determine the safety, tolerability and immunogenicity of the treatment. The patients will be followed-up for another two years to determine long-term safety.
Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
Patellofemoral pain syndrome is one of the most common problems of the knee. It is characterized by anterior knee pain that is aggravated by deep knee flexion, prolonged sitting, and repetitive flexion/extension. The most widely accepted theory in regards to the source of this pain is that a force imbalance around the knee leads to static patellofemoral malalignment and dynamic patellofemoral maltracking. In turn, this malalignment and maltracking lead to elevated joint contact stresses, which ultimately leads to patellofemoral pain. Current understanding of patellofemroal maltracking is typically focused on static 2D alignment (lateral tilt and displacement). Yet, patellofemoreal pain is most often exacerbated during dynamic events and the patella has complete six degrees of freedom in its movement. More recent studies have been able to quantify patellofemoral kinematics during volitional dynamic tasks and demonstrate that the maltracking problem is more complex than originally postulated. Specifically, in patients with patellofemoral pain, altered kinematics are not limited to excessive patellar lateral translation and tilt, but include excessive patellar superior translation along with excessive flexion and varus rotation. Although these results are useful in demonstrating how specific maltracking patterns could lead to patellofemoral pain, they do not present any associations between a potentially altered force balance around the knee and the observed maltracking patterns. Therefore, the overall goal of this work is to determine the specific sources of maltracking patterns in patellofemoral pain. As part of this overall goal, the purpose of this study is to determine how the loss of force in the vasti medialis muscle alters the dynamic control of patellar kinematics.
The invention discloses a traditional Chinese medicine composition for treating acute suppurative tonsillitis. The acute suppurative tonsillitis belongs to the category of wind-fire tonsillitis, throat pass welling-abscess and rotten tonsillitis in traditional Chinese medicine. Fire heat evil is steamed at the throat through channels to stagnate veins to lead to stagnation of qi and blood, and heat toxin is accumulated to cause swelling to burn blood and flesh to spoil to form carbuncle. The traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, eliminating swelling and removing stasis and relieving sore-throat and pains. The traditional Chinese medicine composition disclosed by the invention is boiled into a soup by applying viola patrinii DC, acuminate violet leaves, hemsleya macrosperma, chondrilla juncea, devil's lantern roots, lens culinaris, trollius chinensis bunge and radix tinosporae and is internally taken. The traditional Chinese medicine composition has a good curative effect, the total effective rate reaches 93.2%, and the curative effect is remarkably superior to that of the control group. The traditional Chinese medicine composition is free from remarkable toxic and side effects.
The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
Left ventricular thrombus (LVT) is a commom complication after ST segment elevation myocardial infarction (STEMI), reperfusion therapy have reduced the incidence of LVT, however, about 6% of all STEMI patients will develop LVT. the risk of LVT development in anterior STEMI with reduced LVEF are as high as 20%. Although current guideline recommend anti-coagulation therapy, but the evidence still based on observational data, there has been inconsistency with the benefit of the coagulation therapy, give the significant increased bleeding risk by superimpose anti-coagulation therapy to the dual anti-platelet therapy. especially in the era of more potent anti-platelet P2Y12 inhibitor widely used clinical. the mechanism of LVT is different from that of the atrial fibrillation in which the risk of systemic embolism is persistent, coagulation bring absolute clinical benefit for high risk patients. however, for LVT developed following STEMI tend to be temporary, majority of thrombus resolve within 1-3 months after STEMI event. more likely a reflection of coagulation system in response to the necrosis of infarct myocardium. The optimal management in LVT after STEMI warrants further exploration. the desiring of randomized controlled clinical trial to compare dual anti platelet + anti-coagulation and dual anti-platelet without anti-coagulation in patient LVT are justified.
For diagnosis of pancreatic tumors, endoscopic ultrasound (EUS) and EUS-guided fine needle aspiration (EUS-FNA) are well established techniques in clinical practice. In the case of EUS, an ultrasonic transducer located at the tip of the echoendoscope allows the endoscopist to visualize the wall of gastrointestinal tract as a series of definable layers corresponding to histology, and also enables detailed images of areas outside of the digestive tract. EUS has a significant clinical impact because it allows assessment of submucosal GI lesions, loco-regional staging of gastrointestinal malignancy, tissue diagnosis by EUS-FNA and staging of pancreaticobiliary lesions, non-small-cell lung carcinoma, and mediastinal disease. In prospective trials, EUS-FNA has been clearly established to be an important diagnostic tool with excellent safety profile.

Olympus has recently made commercially available a new 22 gauge FNA needle with a side port at the needle tip to facilitate the process of FNA and increase the diagnostic yield. There have been preliminary unpublished retrospective data that suggested the yield might be raised. However, there are no prospective multicenter randomized controlled studies to ascertain the validity of the assumption. The aim of this prospective randomized study is to determine whether there is a difference in diagnostic yield between EZ-Shot 2 (model: NA-220H-8022) and EZ-Shot 2 with side port (NA-230H-8022) in patients with pancreatic masses for evaluation. We hypothesize that a FNA needle with a side port could improve the diagnostic yield.
PURPOSE OF REVIEW: To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).
RECENT FINDINGS: Results of G11778A LHON Phase 3 randomized clinical trials with unilateral intravitreal rAAV2/2-ND4 allotopic gene therapy show good safety and unexpected bilateral partial improvements of BCVA (best-corrected visual acuity) with mean logMAR BCVA improvements of up to near ∼0.3 logMAR (3 lines) in the treated eyes and ∼0.25 logMAR (2.5 lines) in the sham-treated or placebo-treated fellow eyes. Final mean BCVA levels after gene therapy were in the range of ∼1.3 logMAR (20/400) bilaterally.
SUMMARY: Bilateral partial improvement with unilateral LHON gene therapy was unanticipated and may be due to treatment efficacy, natural history, learning effect, and other mediators. The overall efficacy is limited given the final BCVA levels. The sequential progressive visual loss and varied occurrence of spontaneous partial improvement in LHON confound trial results. Future clinical trials with randomization of patients to a group not receiving gene therapy in either eye would help to assess treatment effect. Promising future LHON gene therapy strategies include mitochondrially-targeted-sequence adeno-associated virus ('MTS-AAV') for direct delivery of the wild-type mitochondrial DNA into the mitochondria and CRISPR-free, RNA-free mitochondrial base editing systems. Signs of anatomical optic nerve damage and objective retinal ganglion cell dysfunction are evident in the asymptomatic eyes of LHON patients experiencing unilateral visual loss, indicating the therapeutic window is narrowing before onset of visual symptoms. Future treatment strategies utilizing mitochondrial base editing in LHON carriers without optic neuropathy holds the promise of a more advantageous approach to achieve optimal visual outcome by reducing disease penetrance and mitigating retinal ganglion cell loss when optic neuropathy develops.
Participants receive Cadonilimab at a dose of 10 mg/kg, Q3W (Day 1 of each 21 day treatment cycle) via IV infusion, until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraw informed consent, or Cadonilimab treatment over 2 years. During the q3w dosing period of Cadonilimab, participants receive radiotherapy including external beam radiotherapy (EBRT) and followed by brachytherapy.